Cancer Res Treat.  2005 Oct;37(5):294-301.

Prognostic Factors in Non-Hodgkin's Lymphoma Patients Treated by Autologous Stem Cell Transplantation: A Single Center Experience

• Suh C
• Kim SH
• Kim HJ
• Jang G
• Kim EK
• Ko OB
• Kim S
• Sohn HJ
• Lee JS
• Kim W
• Huh J

Abstract

PURPOSE
Autologous stem cell transplantation (ASCT) is increasingly used in patients with non-Hodgkin's lymphoma (NHL). Various clinical parameters-were evaluated to obtain significant predictors of the outcome following ASCT in patients with NHL. MATERIALS AND METHODS: Between April 1994 and December 2003, ASCT was performed on 80 patients with NHL at the Asan Medical Center. RESULTS: Patients had various histological subtypes and disease status. The two year progression free survival (PFS) and overall survival for all patients were 34 and 31%, respectively. A univariate analysis showed the performance status, stage, modified extranodal involvement category, International Prognostic Index (IPI) at mobilization, disease status at mobilization, and history of radiation prior to mobilization as significant predictors of the outcome following ASCT. Four risk groups, with different 2 year PFS, were identified by the age adjusted IPI at mobilization (mAAIPI): low risk 44%; low intermediate risk 40%; high intermediate risk 19%; and high risk 0% (p=.0003). A multivariate analysis revealed 3 significant factors for the PFS: disease status, prior RT and mAAIPI. CONCLUSIONS: The mAAIPI was found to be an independent predictor of the outcome of NHL patients undergoing ASCT. This powerful prognostic tool should be used to evaluate potential candidates for ASCT.

Keyword

Non-Hodgkin's lymphoma; Autologous peripheral blood stem cell transplantation; Prognosis; Hematopoietic stem cell mobilization

MeSH Terms

Chungcheongnam-do
Disease-Free Survival
Hematopoietic Stem Cell Mobilization
Humans
Lymphoma, Non-Hodgkin*
Multivariate Analysis
Prognosis
Stem Cell Transplantation*
Stem Cells*

Figure

• 

  Fig. 1 Progression free survival (A) and overall survival (B) for all 80 patients. The Kaplan Meier estimate of the proportion of patients remaining progression free at median follow up of 2 years following ASCT was 34%. And overall survival at 2 years was estimated as 31%.

• 

  Fig. 2 Progression free survival according to the 3 clinical parameters (A) disease status at mobilization, (B) history of radiotherapy before mobilization, and (C) age adjusted International Prognostic Index at mobilization, which were the significant predictors of outcome following ASCT on multivariate analysis. CR: complete response, PR: partial response, Rel: chemotherapy sensitive relapse, Ref: primary refractory or refractory relapse, RT: radiotherapy, L: low risk, LI: low intermediate risk, HI: high intermediate risk, H: high risk.

Reference

1. Mink SA, Armitage JO. High dose therapy in lymphomas: a review of the current status of allogeneic and autologous stem cell transplantation in Hodgkin's disease and non Hodgkin's lymphoma. Oncologist. 2001; 6:247–256. PMID: 11423671.

2. Appelbaum FR, Herzig GP, Ziegler JL, Graw RG, Levine AS, Deisseroth AB. Successful engraftment of cryopreserved autologous bone marrow in patients with malignant lymphoma. Blood. 1978; 52:85–95. PMID: 350316.

3. Philip T, Armitage JO, Spitzer G, Chauvin F, Jagannath S, Cahn JY, et al. High dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate grade or high grade non Hodgkin's lymphoma. N Engl J Med. 1987; 316:1493–1498. PMID: 3295541.

4. Vose JM, Anderson JR, Kessinger A, Bierman PJ, Coccia P, Reed EC, et al. High dose chemotherapy and autologous hematopoietic stem cell transplantation for aggressive non Hodgkin's lymphoma. J Clin Oncol. 1993; 11:1846–1851. PMID: 8105034.

5. Petersen FB, Appelbaum FR, Hill R, Fisher LD, Bigelow CL, Sanders JE, et al. Autologous marrow transplantation for malignant lymphoma: a report of 101 cases from Seattle. J Clin Oncol. 1990; 8:638–647. PMID: 2313333.

6. Rapoport AP, Lifton R, Constine LS, Duerst RE, Abboud CN, Liesveld JL, et al. Autotransplantation for relapsed or refractory non Hodgkin's lymphoma (NHL): long term follow up and analysis of prognostic factors. Bone Marrow Transplant. 1997; 19:883–890. PMID: 9156261.

7. Phillips GL, Fay JW, Herzig RH, Lazarus HM, Wolff SN, Lin HS, et al. The treatment of progressive non Hodgkin's lymphoma with intensive chemoradiotherapy and autologous marrow transplantation. Blood. 1990; 75:831–838. PMID: 2302456.

8. A predictive model for aggressive non Hodgkin's lymphoma. The International Non Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993; 329:987–994. PMID: 8141877.

9. Hermans J, Krol AD, van Groningen K, Kluin PM, Kluin Nelemans JC, Kramer MH, et al. International prognostic index for aggressive non hodgkin's lymphoma is valid for all malignancy grades. Blood. 1995; 86:1460–1463. PMID: 7632953.

10. Blay J, Gomez F, Sebban C, Bachelot T, Biron P, Guglielmi C, et al. The international prognostic index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Blood. 1998; 92:3562–3568. PMID: 9808548.

11. Moskowitz CH, Nimer SD, Glassman JR, Portlock CS, Yahalom J, Straus DJ, et al. The international prognostic index predicts for outcome following autologous stem cell transplantation in patients with relapsed and primary refractory intermediate grade lymphoma. Bone Marrow Transplant. 1999; 23:561–567. PMID: 10217186.

12. Cuttica A, Zallio F, Ladetto M, Di Nicola M, Caracciolo D, Magni M, et al. Patients with high risk aggressive lymphoma treated with frontline intensive chemotherapy and autografting evidence of marked differences in outcome between patients with age adjusted International Prognostic Index scores 2 and 3. Cancer. 2003; 98:983–992. PMID: 12942566.

13. Hamlin PA, Zelenetz AD, Kewalramani T, Qin J, Satagopan JM, Verbel D, et al. Age adjusted international prognostic index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B cell lymphoma. Blood. 2003; 102:1989–1996. PMID: 12676776.

14. National Cancer Institute sponsored study of classifications of non Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non Hodgkin's Lymphoma Pathologic Classification Project. Cancer. 1982; 49:2112–2135. PMID: 6896167.

15. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller Hermelink HK, Vardiman J, et al. World health organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting: Airlie House, Virginia, November 1997. J Clin Oncol. 1999; 17:3835–3849. PMID: 10577857.

16. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non Hodgkin's lymphomas. J Clin Oncol. 1999; 17:1244–1253. PMID: 10561185.

17. Suh C, Kim HJ, Kim SH, Kim S, Lee SJ, Lee YS, et al. Low dose lenograstim to enhance engraftment after autologous stem cell transplantation: a prospective randomized evaluation of two different fixed doses. Transfusion. 2004; 44:533–538. PMID: 15043569.

18. Jantunen E, Kuittinen T, Nousiainen T. BEAC or BEAM for high dose therapy in patients with non Hodgkin's lymphoma? A single centre analysis on toxicity and efficacy. Leuk Lymphoma. 2003; 44:1151–1158. PMID: 12916867.

19. Kim H, Sohn HJ, Kim SE, Kang HJ, Park S, Kim S, et al. Lymphocyte recovery as a positive predictor of prolonged survival after autologous peripheral blood stem cell transplantation in T cell non Hodgkin's lymphoma. Bone Marrow Transplant. 2004; 34:43–49. PMID: 15107814.

20. Shipp MA, Abeloff MD, Antman KH, Carroll G, Hagenbeek A, Loeffler M, et al. International consensus conference on high dose therapy with hematopoietic stem cell transplantation in aggressive non Hodgkin's lymphomas: report of the jury. J Clin Oncol. 1999; 17:423–429. PMID: 10458261.

21. Kim HT, Im YH, Suh CI, Park YS, Kang WK, Heo DS, et al. Malignant lymphomas in Korea. J Korean Cancer Assoc. 1992; 24:92–101.